Piramal Pharma (PPLPHARMA) — Announcement

📢 Key Event
Temporary suspension of Ahmedabad facility operations due to heavy rainfall

🔮 What's Next
Operations expected to gradually normalize over the next few days

💡 Investor Takeaway
Shareholders should monitor for any material financial impact from the temporary shutdown.

Piramal Pharma disclosed a temporary suspension of operations at its Ahmedabad manufacturing facilities in Gujarat due to heavy rainfall and flooding, affecting less than 3% of consolidated revenues. The company confirmed employee safety, noted assets are insured, and expects gradual resumption within days as weather improves. No immediate financial impact is anticipated, but ongoing assessments will determine any material effects on operations or assets.

📄 View Original Announcement (PDF)

📊 Stock Analysis — PPLPHARMA ✨ Ask AI About This

About Piramal Pharma Limited (PPLPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹23,244.56 Cr P/E: 582.9

View full PPLPHARMA stock details →

📡 Get AI alerts when PPLPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track PPLPHARMA — Free

💡 Ask AI about this filing

"What is the estimated revenue impact from the Ahmedabad facility shutdown?" "When exactly are operations expected to fully resume?" "What insurance coverage limits apply to flood-related asset damage?"

Ask AI Free →

📊 More PPLPHARMA filings

See all PPLPHARMA filings →

🔥 Also filed on 24 July 2026

CGPOWER CG Power and Industrial Solutions Limited Financial Results OMAXAUTO Omax Autos Limited Financial Results NITCO Nitco Limited Corporate Action LENSKART Lenskart Solutions Limited Annual Report ALLDIGI Alldigi Tech Limited Financial Results RKFORGE Ramkrishna Forgings Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when PPLPHARMA files new disclosures

Track PPLPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.